30 ноя 2017 г. - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.
Добавлено на ленту времени:
Дата:
30 ноя 2017 г.
Сейчас
~ 7 гг и 10 мес назад